<DOC>
	<DOCNO>NCT02713477</DOCNO>
	<brief_summary>Primary Objective : To assess postprandial glucodynamic response 2 dos insulin glargine/lixisenatide fixed-ratio combination compare placebo Japanese patient type 2 diabetes mellitus ( T2DM ) . Secondary Objectives : - To assess pharmacokinetics ( PK ) lixisenatide follow administration 2 different dos insulin glargine/lixisenatide fixed-ratio combination Japanese patient T2DM . - To assess postprandial glucodynamic response insulin glargine/lixisenatide fixed-ratio combination compare insulin glargine alone Japanese patient T2DM . - To assess safety tolerability insulin glargine/lixisenatide fixed-ratio combination Japanese patient T2DM .</brief_summary>
	<brief_title>Postprandial Glucodynamic Response Insulin Glargine/Lixisenatide Fixed Ratio Combination Japanese Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>The total study duration per patient approximately 6 13 week consist 2-28 day screen period , 3-day treatment period , 7-14 day washout period , 1-day end study visit .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Inclusion criterion : Japanese male female patient T2DM diagnose least 1 year prior time screen establish medical history . Patients age 20 75 year screen . Body mass index ≤35 kg/m^2 screening . Glycohemoglobin ≥7.0 % ≤10.0 % screening . Fasting Cpeptide ≥0.6 ng/mL screen . Exclusion criterion : Diabetes T2DM . History metabolic acidosis , include diabetic ketoacidosis within 1 year prior screen . History hypoglycemia unawareness . Hemoglobinopathy hemolytic anemia . History myocardial infarction , stroke , heart failure , history presence clinically significant diabetic retinopathy , history presence macular edema likely require laser treatment within study period . History unexplained pancreatitis , chronic pancreatitis , pancreatectomy , stomach/gastric surgery , inflammatory bowel disease . Clinically relevant history gastrointestinal disease associate prolonged nausea vomiting , include , limited gastroparesis gastroesophageal reflux disease require medical treatment . Personal family history medullary thyroid cancer ( MTC ) genetic condition predispose MTC ( e.g. , multiple endocrine neoplasia syndrome ) . If female , pregnancy breastfeeding . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>